The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The approval was driven by data from the Phase III TULIP-SC trial
The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Subscribe To Our Newsletter & Stay Updated
